{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T17:07:58Z","timestamp":1784308078797,"version":"3.55.0"},"reference-count":32,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T00:00:00Z","timestamp":1740182400000},"content-version":"unspecified","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82304243"],"award-info":[{"award-number":["82304243"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Boehringer-Ingelheim"},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,1,7]]},"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To examine recent patterns regarding oral anticoagulant (OAC) use among patients hospitalised with atrial fibrillation (AF) and quantify the impact of insurance coverage for non-vitamin K oral anticoagulants (NOACs) on quality of care and care inequality regarding OAC use among hospitalised patients with AF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Interrupted time series analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Hospitals in China.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>A total of 36\u2009393 patients hospitalised with non-valvular AF were involved between 2015 and 2019 across China.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary and secondary outcome measures<\/jats:title>\n                    <jats:p>Outcome was the impact of insurance coverage for NOACs on quality of care regarding OAC prescription using interrupted time series analysis with segmented regression models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>OAC prescription rate during hospitalisation was 52.1% (31.3% for warfarin and 20.8% for NOACs) in patients with high-risk AF and 66.3% (29.8% for warfarin and 36.5% for NOACs) in low-risk patients. Insurance coverage for NOACs was associated with an immediate 10.9% (95% CI 7.6% to 14.3%) increase in NOAC prescription and a 0.33% (95% CI 0.08% to 0.58%) increase in the slope of the secular trend of NOAC prescription among all the patients. Disparities in NOAC prescription among hospitals decreased from 18.9 before the insurance coverage for NOACs to 3.4 after that. Similar results were found in patients with high risk of stroke.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>A large gap exists between clinical practice and guideline recommendations regarding OAC prescription among patients hospitalised with AF in China. Insurance coverage may be an effective healthcare strategy to improve quality of care and reduce care disparities regarding OAC prescription among patients with AF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02309398\">NCT02309398<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-088539","type":"journal-article","created":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T22:35:16Z","timestamp":1740263716000},"page":"e088539","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of insurance coverage for non-vitamin K antagonist oral anticoagulants on quality of care and care disparities in patients hospitalised with atrial fibrillation in tertiary hospitals in China: interrupted time series analysis"],"prefix":"10.1136","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct02309398","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Na","family":"Yang","sequence":"first","affiliation":[{"name":"Center for Clinical and Epidemiologic Research, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoqing","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University; National Clinical Research Center for Cardiovascular Diseases, Beijing, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Liu","sequence":"additional","affiliation":[{"name":"Center for Clinical and Epidemiologic Research, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongchen","family":"Hao","sequence":"additional","affiliation":[{"name":"Center for Clinical and Epidemiologic Research, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deyong","family":"Long","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University; National Clinical Research Center for Cardiovascular Diseases, Beijing, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3239-3449","authenticated-orcid":false,"given":"Dong","family":"Zhao","sequence":"additional","affiliation":[{"name":"Center for Clinical and Epidemiologic Research, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3311-0818","authenticated-orcid":false,"given":"Jing","family":"Liu","sequence":"additional","affiliation":[{"name":"Center for Clinical and Epidemiologic Research, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,2,22]]},"reference":[{"key":"2025121601480583000_15.2.e088539.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.11.010"},{"key":"2025121601480583000_15.2.e088539.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2018.05.015"},{"key":"2025121601480583000_15.2.e088539.3","article-title":"Prevalence and risk of atrial fibrillation in China: A national cross-sectional epidemiological study","volume":"23","author":"Shi","year":"2022","journal-title":"Lancet Reg Health West Pac"},{"key":"2025121601480583000_15.2.e088539.4","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.22.8.983"},{"key":"2025121601480583000_15.2.e088539.5","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000665"},{"key":"2025121601480583000_15.2.e088539.6","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa945"},{"key":"2025121601480583000_15.2.e088539.7","first-page":"572","article-title":"Chinese guidelines on diagnosis and management of atrial fibrillation","volume":"51","year":"2023","journal-title":"Chin J Cardiol"},{"key":"2025121601480583000_15.2.e088539.8","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jacc.2020.08.037","article-title":"2020 Update to the 2016 ACC\/AHA Clinical Performance and Quality Measures for Adults With Atrial Fibrillation or Atrial Flutter: A Report of the American College of Cardiology\/American Heart Association Task Force on Performance Measures","volume":"77","author":"Heidenreich","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2025121601480583000_15.2.e088539.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62343-0"},{"key":"2025121601480583000_15.2.e088539.10","doi-asserted-by":"crossref","first-page":"317","DOI":"10.5582\/bst.2022.01278","article-title":"Contemporary oral anticoagulant therapy of patients with atrial fibrillation in China: Status, obstacles, and strategies for improvement","volume":"16","author":"Shang","year":"2022","journal-title":"Biosci Trends"},{"key":"2025121601480583000_15.2.e088539.11","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1055\/s-0038-1670661","article-title":"Patient-Reported Treatment Satisfaction with Dabigatran versus Warfarin in Patients with Non-Valvular Atrial Fibrillation in China","volume":"118","author":"Geng","year":"2018","journal-title":"Thromb Haemost"},{"key":"2025121601480583000_15.2.e088539.12","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ahj.2021.04.011","article-title":"Financial burden, distress, and toxicity in cardiovascular disease","volume":"238","author":"Slavin","year":"2021","journal-title":"Am Heart J"},{"key":"2025121601480583000_15.2.e088539.13","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.trecan.2021.12.007","article-title":"Role of financial toxicity in perpetuating health disparities","volume":"8","author":"Shah","year":"2022","journal-title":"Trends Cancer"},{"key":"2025121601480583000_15.2.e088539.14","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-020968","article-title":"Rationale and design of the improving Care for Cardiovascular Disease in China (CCC) project: a national registry to improve management of atrial fibrillation","volume":"8","author":"Hao","year":"2018","journal-title":"BMJ Open"},{"key":"2025121601480583000_15.2.e088539.15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32136-1"},{"key":"2025121601480583000_15.2.e088539.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2004.06.041"},{"key":"2025121601480583000_15.2.e088539.17","doi-asserted-by":"publisher","DOI":"10.1159\/000180580"},{"key":"2025121601480583000_15.2.e088539.18","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyw098"},{"key":"2025121601480583000_15.2.e088539.19","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.4150"},{"key":"2025121601480583000_15.2.e088539.20","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.116.012988"},{"key":"2025121601480583000_15.2.e088539.21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0108571","article-title":"Trend of urban-rural disparities in hospital admissions and medical expenditure in China from 2003 to 2011","volume":"9","author":"Fu","year":"2014","journal-title":"PLoS One"},{"key":"2025121601480583000_15.2.e088539.22","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-141-10-200411160-00005"},{"key":"2025121601480583000_15.2.e088539.23","doi-asserted-by":"crossref","first-page":"306","DOI":"10.5853\/jos.2020.01886","article-title":"Anticoagulation in Patients with End-Stage Renal Disease and Atrial Fibrillation: Confusion, Concerns and Consequences","volume":"22","author":"Goel","year":"2020","journal-title":"J Stroke"},{"key":"2025121601480583000_15.2.e088539.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.01.098"},{"key":"2025121601480583000_15.2.e088539.25","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ahj.2017.08.011","article-title":"International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries","volume":"194","author":"Steinberg","year":"2017","journal-title":"Am Heart J"},{"key":"2025121601480583000_15.2.e088539.26","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1097\/CM9.0000000000001151","article-title":"Contemporary characteristics, management, and outcomes of patients hospitalized for atrial fibrillation in China: results from the real-world study of Chinese atrial fibrillation registry","volume":"133","author":"Zhao","year":"2020","journal-title":"Chin Med J"},{"key":"2025121601480583000_15.2.e088539.27","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.008643"},{"key":"2025121601480583000_15.2.e088539.28","doi-asserted-by":"publisher","DOI":"10.1002\/clc.22077"},{"key":"2025121601480583000_15.2.e088539.29","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-018180","article-title":"Trends in initiation of direct oral anticoagulant therapies for atrial fibrillation in a national population-based cross-sectional study in the French health insurance databases","volume":"8","author":"Huiart","year":"2018","journal-title":"BMJ Open"},{"key":"2025121601480583000_15.2.e088539.30","doi-asserted-by":"crossref","DOI":"10.3346\/jkms.2018.33.e163","article-title":"Impact of the Health Insurance Coverage Policy on Oral Anticoagulant Prescription among Patients with Atrial Fibrillation in Korea from 2014 to 2016","volume":"33","author":"Ko","year":"2018","journal-title":"J Korean Med Sci"},{"key":"2025121601480583000_15.2.e088539.31","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-072098","article-title":"Estimated impact from the withdrawal of primary care financial incentives on selected indicators of quality of care in Scotland: controlled interrupted time series analysis","volume":"380","author":"Morales","year":"2023","journal-title":"BMJ"},{"key":"2025121601480583000_15.2.e088539.32","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/bcp.13150","article-title":"Effects of policy interventions on the introduction of novel oral anticoagulants in Stockholm: an interrupted time series analysis","volume":"83","author":"Komen","year":"2017","journal-title":"Br J Clin Pharmacol"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-088539","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T09:48:15Z","timestamp":1765878495000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-088539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":32,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2,22]]},"published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1136\/bmjopen-2024-088539"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-088539","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2]]}}}